abiraterone acetate, Janssen Biotech, MAGNITUDE, mCRPC, Niraparib
Niraparib and abiraterone acetate plus prednisone is approved by FDA for BRCA-mutated metastatic castration-resistant prostate cancer
August 2023: The fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), along with prednisone, has been approved by the Food and Drug Administration for adult patients with castration-resista..
gallium Ga 68 gozetotide, Locametz, lutetium Lu 177 vipivotide tetraxetan, mCRPC, Novartis, Pluvicto, PSMA
Pluvicto is approved by FDA for metastatic castration-resistant prostate cancer
April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific mem..